Zobrazeno 1 - 10
of 124
pro vyhledávání: '"Andrew R, Belch"'
Autor:
Jitra Kriangkum, Sarah N Motz, Tanner Mack, Sara Beiggi, Eva Baigorri, Hemalatha Kuppusamy, Andrew R Belch, James B Johnston, Linda M Pilarski
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0137232 (2015)
The immunoglobulin heavy chain (IGH) gene rearrangement in chronic lymphocytic leukemia (CLL) provides a unique molecular signature; however, we demonstrate that 26/198 CLL patients (13%) had more than one IGH rearrangement, indicating the power of m
Externí odkaz:
https://doaj.org/article/7f4617d9519e44029a8c3809cf2e4678
Autor:
Michael P Chu, Jessica Lieffers, Sunita Ghosh, Andrew R Belch, Neil S Chua, Amelie Fontaine, Randeep Sangha, A Robert Turner, Vickie E Baracos, Michael B Sawyer
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0127589 (2015)
Skeletal muscle radio-density (SMD) measures muscle radiation attenuation (in Hounsfield Units, HU) on computed tomography (CT) scans. Low SMD is prognostic of poor survival in melanoma, however its significance is unknown for hematologic malignancie
Externí odkaz:
https://doaj.org/article/3b2c5db253784f3cbe2ec1f0f1bf542b
Autor:
Hemalatha Kuppusamy, Helga M Ogmundsdottir, Eva Baigorri, Amanda Warkentin, Hlif Steingrimsdottir, Vilhelmina Haraldsdottir, Michael J Mant, John Mackey, James B Johnston, Sophia Adamia, Andrew R Belch, Linda M Pilarski
Publikováno v:
PLoS ONE, Vol 9, Iss 6, p e100691 (2014)
Genetic variations in the hyaluronan synthase 1 gene (HAS1) influence HAS1 aberrant splicing. HAS1 is aberrantly spliced in malignant cells from multiple myeloma (MM) and Waldenstrom macroglobulinemia (WM), but not in their counterparts from healthy
Externí odkaz:
https://doaj.org/article/3b3843e51fba436ebe244549f552ce0a
Autor:
Sean Dolan, Max Sherry, Irwindeep Sandhu, Christine Chen, Arleigh McCurdy, Christopher P. Venner, Andrea Kew, Annette E. Hay, Martha L Louzada, Richard Leblanc, Tony Reiman, Gail T. McDonald, Marc Lalancette, Bingshu E. Chen, Andrew R. Belch, Engin Gul, Donna E. Reece, Bethany Monteith, Darrell White
Publikováno v:
American journal of hematologyREFERENCES. 96(5)
The MCRN-003/CCTGMYX.1 is a single arm phase II trial of weekly carfilzomib, cyclophosphamide and dexamethasone (wKCd), exploring a convenient immunomodulator (IMiD)-free regimen in relapsed myeloma. Weekly carfilzomib (20/70 mg/m2 ), dexamethasone 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81e3e9be84a694dca075905c2a1a8cfb
https://pubmed.ncbi.nlm.nih.gov/33650179
https://pubmed.ncbi.nlm.nih.gov/33650179
Publikováno v:
PLoS ONE, Vol 8, Iss 4 (2013)
Externí odkaz:
https://doaj.org/article/889bc9ae3b46428aaf3cfca23ed897f0
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e53469 (2013)
Aberrant pre-mRNA splice variants of hyaluronan synthase 1 (HAS1) have been identified in malignant cells from cancer patients. Bioinformatic analysis suggests that intronic sequence changes can underlie aberrant splicing. Deletions and mutations wer
Externí odkaz:
https://doaj.org/article/09a215c6e96f43fe8ed4e336aa3cd092
Autor:
Mary M Zheng, Zhifang Zhang, Kyle Bemis, Andrew R Belch, Linda M Pilarski, John E Shively, Julia Kirshner
Publikováno v:
PLoS ONE, Vol 8, Iss 3, p e58504 (2013)
Multiple myeloma (MM) is an incurable bone marrow malignancy of the B cell lineage. Utilizing multiplex Luminex technology we measured levels of 25 cytokines in the plasma of normal donors (n = 177), those with monoclonal gammopathy of undetermined s
Externí odkaz:
https://doaj.org/article/c3bef10258664c6bb928a4460b4e9946
Autor:
Jitra Kriangkum, Sarah N Motz, Carina S Debes Marun, Sandrine T Lafarge, Spencer B Gibson, Christopher P Venner, James B Johnston, Andrew R Belch, Linda M Pilarski
Publikováno v:
PLoS ONE, Vol 8, Iss 5, p e64927 (2013)
Clonal diversity in multiple myeloma (MM) includes both MM-related and MM-unrelated clonal expansions which are subject to dominance exerted by the MM clone. Here we show evidence for the existence of minor but highly expanded unrelated B-cell clones
Externí odkaz:
https://doaj.org/article/8f7197a1402f47988aaf48a320c703d0
Autor:
Paul G. Richardson, Kenneth C. Anderson, Jesús F. San-Miguel, Andrew R. Belch, Andrew Spencer, Ka Lung Wu, Adam Walter-Croneck, Morio Matsumoto, Sagar Lonial, Katja Weisel, Sebastian Grosicki, Maria-Victoria Mateos, Hermann Einsele, Ivan Spicka, Darrell White, Meral Beksac, Ying-Ming Jou, Masafumi Taniwaki, Philippe Moreau, Donna E. Reece, Alex Ganetsky, Robert Z. Orlowski, Hila Magen, Anil K. Singhal, Ofer Shpilberg, Christoph Röllig, Meletios A. Dimopoulos, Heather Oakervee
Publikováno v:
Blood Cancer Journal
Digital.CSIC. Repositorio Institucional del CSIC
instname
Blood Cancer Journal, Vol 10, Iss 9, Pp 1-10 (2020)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Blood Cancer Journal, Vol 10, Iss 9, Pp 1-10 (2020)
Prolonging overall survival (OS) remains an unmet need in relapsed or refractory multiple myeloma (RRMM). In ELOQUENT-2 (NCT01239797), elotuzumab plus lenalidomide/dexamethasone (ERd) significantly improved progression-free survival (PFS) versus lena
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8b898853c5ff7619272a8e462194b8f
https://doi.org/10.1038/s41408-020-00357-4
https://doi.org/10.1038/s41408-020-00357-4
Autor:
Linda M. Pilarski, Eva Baigorri, Michael J. Mant, Patrick M. Pilarski, Penelope Adamson, Heddy Zola, Andrew R. Belch
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 2 (2008)
Potential progenitor B cell compartments in multiple myeloma (MM) are clinically important. MM B cells and some circulating MM plasma cells express CD20, predicting their clearance by treatment with anti-CD20. Here we describe two types of clonotypic
Externí odkaz:
https://doaj.org/article/40b9e3acdacd4dc9b94e25640b494818